Research funded by the Meningitis Trust

 Members of the Research Advisory Panel

The strategic aim of the Meningitis Trust is to work towards the eradication of meningitis as a serious medical condition. Since 1985 the Meningitis Trust has awarded grants totalling over £5 million for funding research into all aspects of the Meningitis. Meningitis Trust research grants have been instrumental in funding research that has led to vital developments in vaccines and treatments for meningitis.

With the availability of effective vaccines to prevent some types of meningitis and septicaemia, and the potential production of a vaccine to prevent meningococcal group B disease within the next five years, the Trust is now focusing its research on the after-effects of these devastating diseases.

Research funded by the Meningitis Trust

Learning about the results and outcomes of recently completed research into meningitis is vital in developing clinical practice. In this section you can find summaries of the results of recently completed research.

Development of a specific Quality of Life scale for adolescents and young adults after meningococcal disease

Characterisation of the immune response to specific antigens in sera following vaccination with OMV vaccines and in sera from patients convalescing from group B disease Feavers research

 Infection with an Avirulent phoP Mutant of Neisseria meningitides Confers Broad Cross-Reactive immunity

 Carriage of hypervirulent meningococci before and after the introduction of serogroup C conjugate polysaccharide vaccine in the UK

 Neisseria lactamica as a vaccine against meningococcal disease

 [Cu,Zn]-cofactored superoxide dismutase (SodC) as a vaccine to prevent serogroup B meningococcal disease

Analysis of mucosal immunity to Neisseria meningitidis after serogroup B vaccination

Members of the Research Advisory Panel

The Research Advisory Panel is made up of a group of scientists, clinicians and professionals all of whom have extensive knowledge of meningitis and its related issues

For more information on our panel members click here.